Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 72%
filed 2026-06-04
Abeona disclosed a Pre-IND meeting with the FDA on June 3, 2026 regarding ABO-701, a novel engineered T-cell therapy for prostate cancer, with plans to submit an IND application in 2027. While this represents material regulatory progress for a clinical-stage biopharmaceutical company, it does not fit neatly into the specific event categories (not an earnings release, executive change, M&A activity, impairment, or other defined event type). The disclosure is material because FDA regulatory milestones and clinical development timelines are central to investor assessment of biotech companies' prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-04
Item 5.03
The Company filed a Certificate of Designation creating 400 shares of Series A Preferred Stock with a stated value of $12,000 per share, bearing an 8% annual preferred return and subject to redemption at 110% of liquidation value, representing a material capital structure change.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-04
Item 2.03
The Company created a direct financial obligation whose specific nature is incorporated by reference from Item 1.01 and cannot be precisely determined from the available Item classifications.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
Item 1.01
MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement granting worldwide exclusive rights to develop, manufacture, and commercialize products under the MIRA-55 and SKNY-1 programs. The amendment does not materially modify previously disclosed core economic terms, suggesting a restructuring or clarification of existing arrangements.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
The filing discloses release of an on-demand video presentation and investor materials detailing pre-clinical findings on Ampligen® (rintatolimod) as a potential prophylactic/early-onset antiviral treatment for Ebola virus disease. While this represents material disclosure of clinical/research developments for the company's lead drug candidate, it does not fit cleanly into standard event categories (not earnings, M&A, executive changes, impairment, litigation, or cybersecurity). The forward-looking nature and clinical development focus suggest investor-material information about the company's pipeline, warranting classification as other_material rather than a more specific category.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-04
The filing discloses a board-approved extension of the deadline to consummate an initial business combination (from June 3, 2026 to July 3, 2026), with an additional $13,897.14 deposited into the trust account. While this is a routine administrative action for a SPAC, the extension of a business combination deadline is material to investors assessing the registrant's progress toward its stated objective and the timeline for potential liquidity events. This does not fit neatly into the more specific event categories (not M&A completion, not going concern, not a covenant breach), so "other_material" is most appropriate.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-04
The filing discloses a direct financial obligation under Item 2.03: issuance of a $34,330.96 unsecured promissory note to the Sponsor and United Hydrogen Group Inc. to fund an extension of the business combination deadline (the nineteenth extension, now to July 6, 2026). While this creates a debt obligation, it does not fit neatly into the more specific event categories (not a covenant breach, not a going-concern disclosure, not a restatement). The repeated extensions and reliance on sponsor funding to extend the SPAC timeline are material to investors assessing the registrant's ability to complete its business combination.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-04
The filing discloses termination of a material definitive agreement (Item 1.02) with Catalyst Group, a company controlled by the Company's Chairman Ronald T. Nixon and holding >5% beneficial ownership. The termination is tied to a strategic shift toward soft tissue repair and bone fusion products. While this is a contract termination rather than a traditional M&A, executive, or financial event, it is material because it eliminates an ongoing advisory relationship with a related party and signals a strategic pivot. The lack of a standard event type that cleanly captures a related-party service agreement termination warrants classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-04
The 8-K discloses a press release letter to shareholders announcing "an update on various business matters" under Item 7.01 (Regulation FD Disclosure), but the actual content of the press release is not provided in the filing body—only a reference to Exhibit 99.1. Without access to the exhibit text, the specific nature of the business update cannot be determined. Given the vague language and lack of substantive disclosure in the body, this is classified as other_material with low confidence, as it could encompass earnings, M&A activity, executive changes, or other material events depending on the exhibit content.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-04
The filing discloses termination of a material definitive agreement—specifically a ChEF Purchase Agreement with Chardan Capital Markets worth up to $500 million and its associated Registration Rights Agreement, both terminated effective May 28, 2026. While Item 1.02 covers termination of material agreements, this does not fit neatly into the more specific event categories (it is not M&A activity, a covenant breach, or dilutive issuance). The loss of a $500 million equity financing commitment is material to a reasonable investor's assessment of the company's capital resources and liquidity.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
The filing discloses receipt of initial purchase orders for a $125 million U.S. Program and expansion of a partnership with Global Combat Collective via Item 7.01 (Regulation FD Disclosure). While the specific nature of the program and partnership is not detailed in the 8-K body itself, the magnitude ($125 million in purchase orders) and the emphasis on partnership expansion suggest a material business development event. However, without access to the attached press release (Exhibit 99.1), the precise classification is uncertain—this could relate to a significant contract, strategic partnership, or other material business event that does not fit neatly into the more specific event categories.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-04
Item 5.03
The company disclosed a 1-for-10 reverse stock split effective June 17, 2026, a material capital structure change that affects share price, trading mechanics, and all shareholder holdings uniformly.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-04
Item 7.01
FingerMotion announced an agreement in principle to enter into a Memorandum of Understanding with BlueFlare Energy Solutions for development of behind-the-meter AI compute infrastructure across Western Canada. While the MOU is substantially non-binding regarding principal commercial terms and subject to future definitive agreements, the disclosure describes a foundational strategic partnership that would position BlueFlare as FingerMotion's exclusive development partner across Alberta, British Columbia, and Saskatchewan. This represents a material strategic initiative that would affect a reasonable investor's assessment of the company's growth strategy and capital deployment plans, but does not fit cleanly into the M&A taxonomy (no acquisition, merger, or change of control is contemplated at this stage) and is better classified as a material strategic partnership announcement.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-04
Item 8.01
This Item 8.01 discloses the entry into underwriting and certificate purchase agreements for a commercial mortgage-backed securities (CMBS) securitization scheduled to close on June 24, 2026, with $570.2 million in public certificates and $63.4 million in private certificates. While this represents a material financing/capital-raising event for the registrant, it does not fit cleanly into the standard 8-K taxonomy categories (not M&A, not earnings, not an executive event, not a covenant breach or impairment). The disclosure is material to investors as it describes the structure and terms of a significant securitization transaction, but the event type is best classified as "other_material" given the absence of a more specific category for securitization issuances or structured finance transactions.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-04
Item 8.01
LanzaTech disclosed that its joint venture Shougang LanzaTech completed an IPO on the Hong Kong Stock Exchange on June 3, 2026, raising approximately US$75 million gross proceeds with an implied market capitalization of US$750 million. While the Company did not sell shares or receive proceeds, its ownership stake was diluted from 9.31% to 8.38%, and the Company is evaluating potential accounting impacts on the carrying value of its investment under U.S. GAAP. This represents a material event affecting the Company's significant equity investment, though it does not fit neatly into the more specific categories (not an M&A activity initiated by the Company, not a restatement, not a going-concern issue).
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-04
Item 8.01
Bakkt invested approximately $9.4 million to acquire 47.5 million warrants in Transchem Ltd., an Indian BSE-listed company, pursuant to a preferential allotment. While this represents a material capital deployment and equity investment activity, it does not fit cleanly into the M&A taxonomy (no acquisition, merger, or change of control) and is disclosed under Item 8.01 (Other Events) rather than Item 1.01. The investment is material to a reasonable investor assessing the company's capital allocation and strategic positioning, but the specific nature—a warrant subscription in a foreign listed company—lacks a more precise event classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
Item 5.03
Stockholder-approved amendments to Lyft's Certificate of Incorporation (Proposals 5 and 6) became effective on June 3, 2026. The specific substantive nature of the amendments is not detailed in the 8-K Item 5.03 disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-04
Item 1.01
TIC Solutions entered into a Third Amendment to its Credit Agreement on June 2, 2026, which reduced interest rates by 25 basis points and increased the Letter of Credit Sublimit to $50 million. This material modification to the Company's debt structure affects borrowing costs and credit availability.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-04
Item 8.01
The filing discloses two material debt-related transactions: (1) an expected amendment to the Credit Agreement to extend maturity of $848 million in term loans to 2033, reduce pricing, and upsize by $353 million, and (2) a partial redemption of $350 million of the $550 million outstanding 2028 Notes at par plus accrued interest, conditioned on refinancing proceeds. While these are significant capital structure events affecting the company's debt profile and financial obligations, they do not fit cleanly into the specific covenant_breach, ma_activity, or dilutive_issuance categories—they represent refinancing and debt management activities that would materially affect a reasonable investor's assessment of the company's leverage and liquidity position.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
Item 2.03
This Item 2.03 disclosure describes the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of New York. While the filing explicitly states "consolidated obligations issuance is material to the Bank," the prose does not disclose a specific new debt issuance event with quantified amounts or dates—rather, it provides regulatory framework and general disclosure methodology. The actual Schedule A referenced would contain the material details, but those specifics are not included in this section. This appears to be a standing disclosure about the Bank's debt issuance program rather than a discrete material event, making it difficult to classify under the more specific event types; accordingly, `other_material` is most appropriate.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-04
Item 2.05
The disclosure reports a Board-committed plan to close a manufacturing facility in the Netherlands with expected pre-tax charges of $80–110 million, primarily from asset write-downs, inventory charges, and employee severance. While this is a material restructuring event affecting future financial results, it does not fit cleanly into the "material_impairment" category (which typically covers asset write-downs already recognized) or any other specific taxonomy event. The charges are prospective and tied to an exit/disposal activity, making "other_material" the most appropriate classification for this significant operational restructuring.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-04
Item 8.01
The filing discloses authorization and declaration of quarterly dividends on both common stock ($0.01 per share) and preferred stock ($0.484375 per share), with specific payment and record dates. While dividend declarations are routine corporate actions, they are material to shareholders as they affect distributions and are typically disclosed in 8-K filings. This does not fit the more specific earnings_release category (which typically involves financial results) nor any other defined event type, making other_material the appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-04
Item 8.01
iPower announced completion of a ~$1 million purchase of USDai cryptocurrency and plans to stake it into sUSDai as part of an "AI infrastructure investment strategy." This represents a material capital deployment into digital assets that would affect investor assessment of the company's strategic direction and asset composition, but does not fit neatly into standard M&A, impairment, or other predefined categories. The company's explicit 8-K filing and press release signal materiality despite the non-traditional asset class.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
Item 1.01
The filing discloses a settlement agreement between Invech Holdings and Arnold F. Sock involving the issuance of IVHI shares to settle a balance due. While Item 1.01 typically covers M&A activity, this settlement agreement does not constitute a material acquisition, disposition, merger, or change of control. The transaction involves share issuance to settle a liability, which could be characterized as a dilutive issuance, but the primary focus is on settling an existing obligation rather than raising capital. The materiality of the settlement and the share issuance warrants disclosure, but the event does not cleanly fit the standard M&A taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-04
Item 8.01
The filing discloses that the Android version of SafeDeal Connect, the Company's core mobile application, was removed from the Google Play Store and remains unavailable. This represents a material disruption to the Company's primary product offering and user accessibility, affecting a significant portion of the mobile user base. While the Company is working to restore availability, the inability to provide a definitive restoration timeline due to Google's review process creates material uncertainty about product availability and revenue impact.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-04
Item 5.03
The company executed a 1-for-500 reverse stock split, effective June 5, 2026, reducing outstanding shares from approximately 20.2 billion to approximately 40.4 million. The reverse split was approved by the Board and shareholders and was accompanied by a name change and trading symbol change.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
Item 1.01
Northwest Natural Holding Company entered into a Note Purchase Agreement on June 4, 2026, to issue $120 million in aggregate principal amount of senior notes across three series (Series E, F, and G) with maturities ranging from 2031 to 2036, creating material direct financial obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-04
Item 8.01
NW Natural Water Company, LLC, a subsidiary of Northwest Natural Holding Co, issued $75 million in aggregate principal amount of senior notes ($33M Series A at 5.15% due 2031 and $42M Series B at 5.58% due 2036) on June 4, 2026, with proceeds to be used for general corporate purposes and repayment of existing indebtedness.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
Item 7.01
The Company declared a monthly distribution for its shareholders, specifying per-share amounts across six share classes with varying distribution fees. This routine REIT distribution disclosure is material to investors assessing income yield and cash flow.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
Item 2.03
KKR Private Equity Conglomerate LLC increased its revolving credit facility by $100 million, raising total commitments from $1.0 billion to $1.1 billion with an accordion feature allowing expansion to $1.5 billion. This routine credit facility expansion affects the company's capital structure and liquidity position.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-04
Item 2.03
Franklin BSP Real Estate Debt, Inc. entered into a Master Repurchase Agreement with Barclays Bank PLC with no maximum commitment and no initial maturity date, creating a direct financial obligation. This unlimited commitment structure and perpetual nature make it material to investors assessing the Company's capital structure and leverage.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 2.03
Nordson established a $1.2 billion commercial paper program on June 2, 2026, creating a direct financial obligation under Item 2.03. While this is a material financing arrangement that would affect investor assessment of the company's liquidity and capital structure, it does not fit cleanly into the more specific event categories (it is not a covenant breach, dilutive issuance, or M&A activity). The commercial paper program represents a new debt facility rather than a discrete material event like a restatement or executive change, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
This disclosure reports a material regulatory settlement in PSCo's electric rate case with the Colorado Public Utilities Commission, resulting in a $225 million revenue increase (6.3%) and a 9.3% ROE. While regulatory rate proceedings are significant to utility investors, this settlement does not fit neatly into the standard 8-K event taxonomy—it is neither a discrete M&A transaction, covenant breach, impairment, nor executive action. The disclosure is material because it affects PSCo's future revenue and profitability, but the event type is best classified as "other_material" given the regulatory settlement context.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 7.01
The filing discloses a press release providing an update on operating metrics for Q2 2026 under Item 7.01 (Regulation FD Disclosure). While this resembles an earnings release in substance, it is explicitly characterized as an "update on certain operating metrics" rather than a full financial results disclosure, and is filed under Item 7.01 rather than Item 2.02 (Results of Operations). The material nature of operating metrics for a transportation company and the public announcement warrant materiality classification, but the ambiguity between partial operating metrics and full earnings results supports the broader "other_material" category.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 1.01
Arch Capital entered into an underwriting agreement to issue $2.0 billion in senior notes, consisting of $600 million due 2036 at 5.250% and $1.4 billion due 2056 at 5.950%. The offering was priced on June 2, 2026, representing a material debt financing event affecting the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-03
Item 8.01
The filing discloses a press release dated June 3, 2026, under Item 8.01 (Other Events) but provides no substantive detail about the press release's content. Without access to Exhibit 99.1, the specific event cannot be determined. Given Comcast's size and the formal 8-K filing, the event is likely material, but the event type cannot be reliably classified without knowing what the press release announces.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
ADC Therapeutics announced positive topline data from the Phase 3 LOTIS-5 confirmatory trial of ZYNLONTA plus rituximab in relapsed/refractory DLBCL, meeting the primary endpoint of progression-free survival (HR=0.73, p=0.008) with improved overall response and complete response rates versus R-GemOx, supporting a planned supplemental BLA submission.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 5.03
Sphere 3D filed articles of amendment on May 29, 2026, establishing a new Series I Preferred Stock with 8% PIK dividends, conversion rights contingent on CEO Joel Block's tenure, liquidation preferences, and a Nasdaq Exchange Cap limitation. This creates a new class of senior securities with significant economic rights and protective provisions affecting capital structure and dilution risk.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
Everest Group is disclosing a material restructuring of its reportable segments effective January 1, 2026, following the sale of its Commercial Retail Insurance business to AIG. The company is recasting significant sections of its 2025 Form 10-K (Business, MD&A, Financial Statements, and Segment Reporting) to retroactively reflect the new three-segment structure (Reinsurance Treaty, Global Wholesale & Specialty, and Legacy). While this is a segment reorganization rather than a discrete event type in the taxonomy, it represents a material change in how the company manages and reports its business that would affect investor understanding of financial performance and composition.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 7.01
The disclosure describes negotiations to amend the Master Services Agreement with Grand Canyon University, the Company's most significant partner representing a substantial portion of revenue. The proposed amendments would extend the initial term by eight years, restructure fee calculations, eliminate GCU's termination-for-convenience rights, and modify non-renewal fees. The Company acknowledges potential revenue reductions of $4–6 million in Q3–Q4 2026 and operating income impact up to $1 million per quarter, which is material to investor assessment. While this is a potential material contract amendment rather than a completed M&A transaction or other more specific event type, it warrants disclosure as a material event affecting the registrant's most critical business relationship.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 8.01
TransCode disclosed results from its Phase 1a dose escalation clinical trial for TTX-MC138 via press release on June 3, 2026. While this is a clinical trial update rather than a formal earnings release, the disclosure of Phase 1a trial results for a therapeutic candidate is material to investors evaluating the company's pipeline progress and development timeline. The forward-looking statements section explicitly references "the timing, conduct and results of TransCode's Phase 1a and Phase 2a clinical trials" and "the therapeutic potential of TTX-MC138," confirming the materiality of these trial results to the company's prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 8.01
The Company entered into a Consent Agreement with CoBank and other lenders regarding its Credit Agreement, using $68 million of proceeds from the tower sale transaction to repay revolving loan debt. The consent arrangement reflects material debt management and lender coordination in connection with the asset sale.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 1.01
The filing discloses entry into a material definitive agreement (Item 1.01) — specifically a Ninth Amendment to a Loan and Servicing Agreement dated December 2, 2015, extending the maturity date from June 2, 2026, to September 30, 2026. While this is a debt refinancing or extension activity, it does not fit cleanly into the M&A taxonomy (which focuses on acquisitions, dispositions, mergers, or changes of control). The amendment extends an existing credit facility rather than creating a new material acquisition or disposition, making "other_material" the most appropriate classification for this debt restructuring event.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 1.04
Hallador Energy's subsidiary Sunrise Coal received an imminent danger order from MSHA on May 28, 2026, under Section 107(a) of the Mine Act at Oaktown Fuels Mine No. 1. While this is a mandatory Item 1.04 disclosure under Dodd-Frank Section 1503, the event itself—a regulatory safety order at an operating mine—is material to investors assessing operational and regulatory risk, even though no injuries occurred and production was not interrupted. The company disputes the order and reserves the right to contest it.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 7.01
The Board of Directors authorized an increase in the company's share repurchase program from $35 million to $50 million, reflecting management confidence and a material capital allocation decision.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-03
Item 3.03
Item 3.03 discloses a material modification to the rights of security holders, incorporating Item 1.01 by reference. The specific nature of the modification cannot be fully determined from the available information.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
The disclosure describes the consummation of a $150 million IPO and concurrent $3.45 million private placement by a SPAC (special purpose acquisition company), with proceeds placed in trust. While this is a material capital-raising event affecting the registrant's financial position, it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, or dilutive issuance in the traditional sense). SPACs are structured differently from operating companies, and the IPO itself is the primary business event rather than a subsequent equity issuance.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
IDEAYA announced a clinical collaboration with Roche to evaluate IDE892 (PRMT5 inhibitor) in combination with RG6505 (pan-RAS inhibitor) in MTAP-deleted pancreatic cancer. This represents a material strategic partnership with a major pharmaceutical company that advances the Company's clinical development pipeline and validates its lead compound in a combination setting. While this does not fit neatly into the more specific event categories (it is not M&A, litigation, impairment, or a traditional earnings/executive event), the collaboration with Roche and the planned Phase 1 combination cohorts constitute material developments affecting the Company's business prospects and investor assessment.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 8.01
REGENXBIO commenced a shareholder-approved Stock Option Exchange Program permitting non-executive employees to exchange underwater stock options with an exercise price of $18.00 or greater for new options granted at fair market value, affecting the company's equity incentive structure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
Dyne Therapeutics announced full enrollment of the registrational expansion cohort (REC) of its Phase 1/2 ACHIEVE trial for z-basivarsen in DM1 patients, with 71 participants enrolled. The company disclosed material clinical development milestones including planned topline data in Q1 2027 and potential BLA submission for Accelerated Approval in Q3 2027, representing significant progress for its lead program.
View raw filing on EDGAR →